Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma

被引：0
|
作者：
Yuzhi Jin
Hui Ren
Qianhua Yue
Wei Wu
Chuan Liu
Yixuan Guo
Peng Zhao
机构：
[1] The First Affiliated Hospital,Department of Medical Oncology
[2] School of Medicine,undefined
[3] Zhejiang University & National Key Laboratory of Advanced Drug Delivery and Release Systems,undefined
[4] Zhejiang University,undefined
[5] Sichuan Academy of Chinese Medicine Sciences,undefined
[6] The First Affiliated Hospital,undefined
[7] Zhejiang University School of Medicine & Key Laboratory of Cancer Prevention and Intervention,undefined
[8] Ministry of Education,undefined
来源：
BMC Cancer | / 24卷
关键词：
Hepatocellular carcinoma; Surrogate endpoint; Milestone survival; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma
    Jin, Yuzhi
    Ren, Hui
    Yue, Qianhua
    Wu, Wei
    Liu, Chuan
    Guo, Yixuan
    Zhao, Peng
    BMC CANCER, 2024, 24 (01)
  • [2] Surrogate Indicators of Overall Survival in Advanced Hepatocellular Carcinoma
    Liu, Hao-Tian
    Sun, Yu-Hong
    Deng, Zhu-Jian
    Zhang, Zi-Yi
    Yang, Da-Long
    Wu, Kun-Jun
    Lan, Xiao-Bu
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2021, 5 (04): : 368 - 370
  • [3] One-year survival for pre-liver transplant chemoembolization of hepatocellular carcinoma.
    Jones, D. T.
    Mangus, R. S.
    Fridell, J. A.
    Vianna, R. M.
    Tector, A. J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S114 - S114
  • [4] Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer
    Zhao, Shen
    Zhang, Zhonghan
    Zhang, Yaxiong
    Hong, Shaodong
    Zhou, Ting
    Yang, Yunpeng
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (11) : 2854 - 2866
  • [5] NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A PREDICTOR OF ONE-YEAR SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB
    Lue, A.
    Bustamante, F. J.
    Inarrairaegui, M.
    Arenas, J. I.
    Serrano, M. T.
    Testillano, M.
    Lorente, S.
    Gil, C.
    De la Torre, M.
    Gomez, A.
    Sangro, B.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S401 - S401
  • [6] TRANSPLACENTAL MELANOMA - ONE-YEAR SURVIVAL
    CAVELL, B
    PEDIATRICS, 1976, 57 (06) : 978 - 979
  • [7] Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma
    Peixoto, Renata D'Alpino
    Renouf, Daniel J.
    Gill, Sharlene
    Cheung, Winson Y.
    Lim, Howard J.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (04) : 259 - 264
  • [8] Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma.
    Huang, Liping
    De Sanctis, Yoriko
    Shan, Minghua
    Bruix, Jordi
    Llovet, Josep
    Cheng, Ann-Lii
    Meinhardt, Gerold
    Nakajima, Keiko
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [9] Surrogate endpoints for overall survival in advanced hepatocellular carcinoma: A meta-analysis
    Saleh, Yacob
    Baskurt, Zeynep
    Farooq, Abdul Rehman
    Goodwin, Rachel Anne
    Knox, Jennifer J.
    Chen, Eric X.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 563 - 563
  • [10] The impact of post-progression survival on overall survival of patients with advanced hepatocellular carcinoma treated by sorafenib therapy
    Terashima, Takeshi
    Yamashita, Tatsuya
    Takata, Noboru
    Nakagawa, Hidetoshi
    Arai, Kuniaki
    Kagaya, Takashi
    Mizukoshi, Eishiro
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY, 2013, 58 : 1221A - 1221A
12345